Table 3.
Initial diseases evaluation of COVID-19 patients.
| 2020-cohort n = 87 |
Omicron-cohort n = 116 |
IPR (95% CI) |
p value | |
|---|---|---|---|---|
| Onset to confirm diagnosis (d) | 6 (4–10) | 1 (1–2) | <0.001 | |
| Severity | ||||
| Sepsis shock (%) | 0 | 0 | ||
| SOFA score | 4 (4–5) | 0 (0–3) | <0.001 | |
| Oxygenation index (mmHg) | 355.71 (309.11–413.98) | 473.43 (434.23–529.50) | <0.001 | |
| Complication (n, %) | ||||
| Lymphopenia | 3 (3.4) | 58 (50) | 14.5 (4.7–44.74) | <0.001 |
| Thrombocytopenia | 18 (20.7) | 6 (5.2) | 0.25 (0.1–0.6) | 0.001 |
| Acute kidney injury | 6 (6.9) | 5 (4.3) | 0.63 (0.2–1.98) | 0.623 |
| Acute liver injury | 2 (2.3) | 4 (3.4) | 1.5 (0.28–8) | 0.952 |
| Acute cardiac injury | 2 (2.3) | 4 (3.4) | 1.5 (0.28–8) | 0.952 |
| Coagulation | 0 | 53 (45.7) | <0.001 | |
| Clinic classification (n, %) | 0.003 | |||
| Nonsevere | 77 (88.5) | 114 (98.3) | ||
| Severe | 10 (11.5) | 2 (1.7) | ||
CI, confidence interval; IPR, incremental prevalence ratios; SOFA, Sequential Organ Failure Assessment.